3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
2
Conditions
Glioma
2
Glioblastoma
2
Recurrence
1
Papillomavirus Infections
1
Medulloblastoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Human Papillomavirus-Related Cervical Carcinoma
1
Astrocytoma
1
Advanced Fallopian Tube Carcinoma
1
Interventions
Temozolomide
393
Radiotherapy
196
Bevacizumab
156
Radiation
77
Magnetic Resonance Spectroscopy
68
Lomustine
47
Surgical Procedures, Operative
42
Carmustine
41
pembrolizumab
39
Irinotecan
38
Nivolumab
32
Specimen Handling
27
Carboplatin
27
Radiosurgery
24
Erlotinib Hydrochloride
24
Chemotherapy, Adjuvant
23
Radiotherapy, Intensity-Modulated
22
Drug Therapy
21
Cyclophosphamide
20
Aminolevulinic Acid
20
O(6)-benzylguanine
17
sargramostim
16
Radiotherapy, Conformal
15
temsirolimus
14
Granulocyte-Macrophage Colony-Stimulating Factor
14
Everolimus
14
Vorinostat
13
Sorafenib
13
poly ICLC
12
atezolizumab
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Glioblastoma
×
Diphtheria Toxoid
×
Clear all
NCT02465268
2025-01-14
ATTAC-II
University of Florida
Phase 2
Completed
175 enrolled
18 charts
NCT03615404
2021-01-28
ATTAC-P
Duke University
Phase 1
Completed
11 enrolled
7 charts